Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Montserrat-Capdevila J, Godoy P, Marsal JR, Cruz I, Solanes M. Effectiveness of influenza vaccination in preventing hospital admission due to exacerbations of chronic obstructive pulmonary disease. Enferm Infecc Microbiol Clin. 2014 Feb;32(2):70-5. doi: 10.1016/j.eimc.2013.02.009
Smets E, Brogan AJ, Hill A, Adriaenssen I, Sawyer AW, Domingo-Pedrol P, Gostkorzewicz J, Ledesma F. Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain. Enferm Infecc Microbiol Clin. 2013 Aug;31(7):430-6.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Serna MC, Real J, Ribes E, Marsal JR, Godoy P, Galvin L. Factors determining antibiotic prescription in primary care. Enferm Infecc Microbiol Clin. 2011 Mar;29(3):193-200. doi: 10.1016/j.eimc.2010.09.012